Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT02268253
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
- NCT02268253 ↗
- Completed
- Stemline Therapeutics, Inc.
- Focused
We haven't built an HCP commentary report on NCT02268253 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02268253 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Myelofibrosis; Chronic Myelomonocytic Leukemia
- Interventions
- Tagraxofusp Injection
- Arms
- Dose Level 1 - Tagraxofusp - 7 micrograms/kilogram (µg/kg)/day - Chronic Myelomonocytic Leukemia · Experimental
- Dose Level 2 - Tagraxofusp - 9 µg/kg/day - Chronic Myelomonocytic Leukemia · Experimental
- Dose Level 3 - Tagraxofusp - 12 µg/kg/day - Chronic Myelomonocytic Leukemia · Experimental
- Dose Level 1 - Tagraxofusp - 7 µg/kg/day - Myelofibrosis · Experimental
- Dose Level 2 - Tagraxofusp - 9 µg/kg/day - Myelofibrosis · Experimental
- Dose Level 3 - Tagraxofusp - 12 µg/kg/day - Myelofibrosis · Experimental
- Enrollment
- 82
- Primary outcomes
- Number of Participants With Dose-limiting Toxicities (DLTs)
- Objective Response Rate (ORR)
- Sponsor
- Stemline Therapeutics, Inc.
- Start
- Feb 10, 2016
- Primary completion
- Mar 27, 2023
- Results posted
- Yes
- Registry record
- NCT02268253 · updated Jan 6, 2025
Publications
linked from the registry- Yacoub A, Ali H, Gupta V, Wang ES, Patnaik MM, Schiller GJ, Taparia M, Mughal TI, Lindsay R, Galleu A, Gupta I, Pemmaraju N. Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis. Blood Neoplasia. 2025 Aug 25;2(4):100165. doi: 10.1016/j.bneo.2025.100165. eCollection 2025 Nov. PubMed 41146971
- Patnaik MM, Ali H, Wang ES, Yacoub A, Foran JM, Gupta V, Schiller GJ, Stevens DA, Talpaz M, Wall S, Lasho TL, Mangaonkar AA, Badar T, Lindsay R, Galleu A, Gupta I, Pemmaraju N, Garcia-Manero G. Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study. Blood Neoplasia. 2025 May 11;2(4):100115. doi: 10.1016/j.bneo.2025.100115. eCollection 2025 Nov. PubMed 40919483